RTP Mobile Logo
Oncology Today with Dr Neil Love: Colorectal Cancer Edition (Audio Program)
Released August 2020

Featuring a roundtable discussion with Drs Axel Grothey and Michael J Overman. (Audio Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gastrointestinal cancers.

    OVERVIEW OF ACTIVITY
    Metastatic colorectal cancer (mCRC) is a common and often lethal condition, and its clinical management is constantly evolving. As published results from ongoing trials lead to the emergence of novel biomarkers and new therapeutic targets and regimens, existing treatment algorithms may be altered. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, this program features a joint discussion with 2 leading gastrointestinal clinical investigators on recently published and emerging research in the management of CRC. By providing access to the latest scientific developments and the perspectives of experts in the field, this CME activity will assist medical oncologists with the formulation of up-to-date clinical management strategies for patients with mCRC.

    LEARNING OBJECTIVES

    • Consider comprehensive biomarker analysis for patients diagnosed with CRC, and use this information to guide evidence-based care.
    • Educate patients about the benefits and risks of approved anti-VEGF, anti-EGFR and other systemic therapies for patients with mCRC, and develop an evidence-based algorithm to sequence these available options based on disease- and patient-specific characteristics.
    • Develop a long-term care plan for individuals diagnosed with mCRC, considering patient and disease characteristics, including biomarker profile, tumor location, prior systemic therapy, symptomatology and personal goals of treatment.
    • Appreciate published research data documenting the efficacy of combined BRAF/EGFR inhibition for patients with CRC with a BRAF V600E mutation to optimally incorporate this therapeutic strategy into current clinical algorithms.
    • Describe available data with approved and investigational immune checkpoint inhibitors for patients with mCRC, and use this information to integrate these agents into clinical practice or refer patients for clinical trials.
    • Devise a rational approach to the incorporation of TAS-102 and regorafenib into the treatment algorithm for patients with mCRC.
    • Counsel patients with mCRC regarding the incidence and manifestation of side effects associated with commonly used targeted agents and immunotherapies, and develop a plan to optimally recognize and manage these toxicities.
    • Recall new data with investigational agents demonstrating promising activity in CRC, and use this information to refer appropriate patients for participation in ongoing trials.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components, enables the participant to earn up to 2.25 (audio) and 2 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THESE CME ACTIVITIES
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide sets, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/OncologyTodayCRC20/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/OncologyTodayCRC20/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/OncologyTodayCRC20/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/OncologyTodayCRC20.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Axel Grothey, MD
    Director, GI Cancer Research
    West Cancer Center and Research Institute
    Chair, OneOncology Research Network
    OneOncology
    Germantown, Tennessee

    Advisory Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Taiho Oncology Inc, Takeda Oncology; Consulting Agreements: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Genentech, a member of the Roche Group; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Merck; Data and Safety Monitoring Board/Committee: Regeneron Pharmaceuticals Inc.

    Michael J Overman, MD
    Professor
    Department of Gastrointestinal Medical Oncology
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Promega Corporation; Consulting Agreements: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, CatalYm, Gritstone Oncology, Merck, Roche Laboratories Inc; Contracted Research: Apexigen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Lilly, Merck, Nouscom, Roche Laboratories Inc, Takeda Oncology; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Merck and Taiho Oncology Inc.

    Release date: August 2020
    Expiration date: August 2021

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio:
Select publications